BREAST CANCER
![Foto de BREAST CANCER](/img/grupo.png)
![Foto de Institut d'Investigació Biomèdica Girona](/img/noimage_org.png)
Institut d'Investigació Biomèdica Girona
Girona, EspañaPublications in collaboration with researchers from Institut d'Investigació Biomèdica Girona (11)
2024
-
Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer
JAMA network open, Vol. 7, Núm. 4, pp. e247811
2019
-
Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients
Aging, Vol. 11, Núm. 9, pp. 2874-2888
-
Neoadjuvant metformin added to systemic therapy decreases the proliferative capacity of residual breast cancer
Journal of Clinical Medicine, Vol. 8, Núm. 12
-
The C allele of ATM rs11212617 associates with higher pathological complete remission rate in breast cancer patients treated with neoadjuvant metformin
Frontiers in Oncology, Vol. 9, Núm. MAR
2018
-
A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: The METTEN study
Oncotarget, Vol. 9, Núm. 86, pp. 35687-35704
2013
-
Basal/HER2 breast carcinomas Integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin)
Cell Cycle, Vol. 12, Núm. 2, pp. 225-245
2012
2011
-
A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines
Breast Cancer Research, Vol. 13, Núm. 6
-
Evidence for a link between TNFRSF11A and risk of breast cancer
Breast Cancer Research and Treatment, Vol. 129, Núm. 3, pp. 947-954
-
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer
PLoS Biology, Vol. 9, Núm. 11
2010
-
Novel anti-fatty acid synthase compounds with anti-cancer activity in HER2+ breast cancer
Annals of the New York Academy of Sciences, Vol. 1210, Núm. 1, pp. 86-92